Biogen Says Data Show Spinraza Improved Motor Function in Later-Onset Spinal Muscular Atrophy
April 30 2019 - 12:52PM
Dow Jones News
By Michael Dabaie
Biogen Inc. (BIIB) said data show individuals with later-onset
spinal muscular atrophy treated with Spinraza regained motor
function that had been previously lost.
Biogen said Tuesday that data from a study of the safety and
tolerability of Spinraza in individuals with later-onset spinal
muscular atrophy were published in the peer-reviewed journal
Neurology.
Patients, aged five up to 19, treated with Spinraza over three
years demonstrated clinically significant improvements in motor
function and stabilization of disease activity, the company said.
One individual gained the ability to walk independently, which
hasn't been previously observed in untreated individuals with SMA
Type 2, Biogen said.
Data also demonstrated long-term durability and safety of
treatment in individuals with later-onset SMA, including SMA Type
3, the company said.
As of March 31, more than 7,500 patients have been treated with
Spinraza in more than 40 countries.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 30, 2019 12:37 ET (16:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024
